LONDON, April 27, 2012 /PRNewswire/ --
Pharma IQ has just published the results of an industry-wide Solubility Report, conducted recently among 3,000 pharmaceutical solubility specialists.
The results showed that improving API solubility is the greatest challenge for nearly 60% of respondents, followed by exploring novel drug delivery routes (specified by 26% of respondents). The rest of the survey participants indicated improving API stability and formulation of biopharmaceuticals as the major issues.
In terms of improving compound solubility, the most popular compound modification strategies used by respondents were developing an amorphous form and adding an excipient. The least popular ones were changing the crystal structure and addition of a salt.
The report was created as a part of the pre-conference research for Improving Solubility Forum, taking place 26-28 June, 2012 in Munich.
The results helped to shape the agenda and final speaker line-up, which features David Elder, Externalisation Director from GlaxoSmithKline who will present his thoughts on model guided formulation development and Lennart Lindfords, Pharmaceutical and Analytical R&D from AstraZeneca, who will be leading a session on Computer Calculations of Poorly Soluble Drug Transport Across the Gastrointestinal Cell Wall.
Other important topics expressed by survey respondents and that will be discussed at the event include:
- The Impact of Solubility During Pharmaceutical Research and Development (Christoph Saal, Senior Manager Molecule Characterisation, Merck)
- The impact of surfactants on dissolution, in-vitro permeability and bioavailability of poorly soluble drugs (Menno Vliestra, Global Supply Chain, Finance and HR, Roche)
- The use the knowledge and experience of other industries to help aid solubility improvement in pharmaceuticals with new updates from Zhijun Liu
Professor, Medicinal Plant Lab, School of Renewable Natural Resources
Louisiana State University Agricultural Centre
To access more reports or to find out more about Pharmaceutical Distribution 2011 please visit http://www.improvingsolubility.com/NEWS, email email@example.com or call +44(0)207-368-1300.
Media contact: Joanna Checinska, +44(0)20-7368-9421, firstname.lastname@example.org - Please contact for more information or images.
Press are invited to attend this important industry forum, if you would like a complimentary press pass please email Joanna Checinska (email@example.com) Related medicine technology :1
. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline2
. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)3
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML4
. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia5
. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management6
. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,9477
. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients8
. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO9
. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)10
. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)11
. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India